Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4817 Comments
1453 Likes
1
Jhournee
Expert Member
2 hours ago
I’m agreeing out of instinct.
👍 178
Reply
2
Richardine
Elite Member
5 hours ago
I read this and now I’m questioning my choices.
👍 300
Reply
3
Neeraja
Daily Reader
1 day ago
Impressed by the dedication shown here.
👍 299
Reply
4
Paytin
Regular Reader
1 day ago
This feels like a hidden message.
👍 249
Reply
5
Walton
Legendary User
2 days ago
I read this and now I’m just here… again.
👍 97
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.